{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:06:17Z","timestamp":1782817577821,"version":"3.54.5"},"reference-count":28,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Corneal fibrosis remains a major cause of visual morbidity, with transforming growth factor-\u03b2 (TGF-\u03b2) signaling playing a central role in this process. Losartan, an angiotensin II type 1 receptor blocker widely used systemically for cardiovascular indications, has recently attracted interest in ophthalmology due to its antifibrotic properties through indirect inhibition of TGF-\u03b2 signaling. In recent years, increasing experimental and early clinical evidence has suggested that topical ophthalmic formulations of losartan may attenuate corneal fibrosis following diverse injuries such as descemetorhexis, alkali burns, and photorefractive keratectomy-related injury. Topical losartan represents a promising, non-cytotoxic antifibrotic strategy in ophthalmology, although human evidence is limited and further randomized controlled clinical trials are required to define its clinical efficacy, optimal indications, timing, posology, formulations, and long-term safety. This review summarizes the biological rationale for the use of topical losartan in ophthalmology, including its molecular mechanisms of action, pharmacologic considerations, and safety profile. We critically review preclinical studies in corneal models, as well as emerging clinical applications.<\/jats:p>","DOI":"10.3390\/jcm15041354","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:41:02Z","timestamp":1770630062000},"page":"1354","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Topical Losartan in Ophthalmology: Rationale, Experimental and Clinical Evidence, and Emerging Clinical Applications"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-6164","authenticated-orcid":false,"given":"Barbara","family":"Burgos-Blasco","sequence":"first","affiliation":[{"name":"Servicio Oftalmologia, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Molero-Senosiain","sequence":"additional","affiliation":[{"name":"Servicio Oftalmologia, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2339-3682","authenticated-orcid":false,"given":"Pilar","family":"Perez-Garcia","sequence":"additional","affiliation":[{"name":"Servicio Oftalmologia, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-9265","authenticated-orcid":false,"given":"Mayte","family":"Ari\u00f1o-Gutierrez","sequence":"additional","affiliation":[{"name":"Servicio Oftalmologia, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3573-0842","authenticated-orcid":false,"given":"Pedro","family":"Arriola-Villalobos","sequence":"additional","affiliation":[{"name":"Servicio Oftalmologia, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC), 28040 Madrid, Spain"},{"name":"Departamento de Oftalmolog\u00eda, Inmunolog\u00eda y ORL, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4450-7471","authenticated-orcid":false,"given":"David","family":"Diaz-Valle","sequence":"additional","affiliation":[{"name":"Servicio Oftalmologia, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC), 28040 Madrid, Spain"},{"name":"Departamento de Oftalmolog\u00eda, Inmunolog\u00eda y ORL, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.exer.2014.09.012","article-title":"The corneal fibrosis response to epithelial-stromal injury","volume":"142","author":"Torricelli","year":"2016","journal-title":"Exp. Eye Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.preteyeres.2015.07.002","article-title":"Progress in corneal wound healing","volume":"49","author":"Ljubimov","year":"2015","journal-title":"Prog. Retin Eye Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.exer.2010.06.021","article-title":"The molecular basis of corneal transparency","volume":"91","author":"Hassell","year":"2010","journal-title":"Exp. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109884","DOI":"10.1016\/j.exer.2024.109884","article-title":"Two-phase mechanism in the treatment of corneal stromal fibrosis with topical losartan","volume":"242","author":"Wilson","year":"2024","journal-title":"Exp. Eye Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ogata, F.T., Verma, S., Coulson-Thomas, V.J., and Gesteira, T.F. (2024). TGF-\u03b2-Based Therapies for Treating Ocular Surface Disorders. Cells, 13.","DOI":"10.3390\/cells13131105"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.2165\/00003495-200565180-00012","article-title":"Losartan: A review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy","volume":"65","author":"Moen","year":"2005","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0163-7258(97)82002-5","article-title":"Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension","volume":"74","author":"McIntyre","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"112931","DOI":"10.1016\/j.biopha.2022.112931","article-title":"Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-\u03b2\/Smad","volume":"149","author":"Zou","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BCR.0b013e3181a28ddb","article-title":"Transforming growth factor-beta and angiotensin in fibrosis and burn injuries","volume":"30","author":"Gabriel","year":"2009","journal-title":"J. Burn Care Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.ki.5001846","article-title":"Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway","volume":"70","author":"Wolf","year":"2006","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Devereux","year":"2002","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/jop.2024.0200","article-title":"Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity","volume":"41","author":"Dutra","year":"2025","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00417-024-06710-8","article-title":"Topical losartan ophthalmic drops\u2014A review of corneal wound healing and topical losartan for managing corneal haze and potential future indications","volume":"263","author":"Abdelghaffar","year":"2025","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/jop.2022.0174","article-title":"Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders","volume":"39","author":"Wilson","year":"2023","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"117857","DOI":"10.1016\/j.biopha.2025.117857","article-title":"Insights from animal studies exploring the efficacy and safety of topical losartan, in prophylaxis and treatment of corneal scarring fibrosis","volume":"183","author":"Dutra","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108940","DOI":"10.1016\/j.exer.2022.108940","article-title":"Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet\u2019s membrane-endothelial excision in rabbits","volume":"216","author":"Sampaio","year":"2022","journal-title":"Exp. Eye Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.11.7.9","article-title":"Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury","volume":"11","author":"Sampaio","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3928\/1081597X-20221026-03","article-title":"Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits","volume":"38","author":"Sampaio","year":"2022","journal-title":"J. Refract. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.12.9.20","article-title":"Topical Losartan Decreases Myofibroblast Generation But Not Corneal Opacity After Surface Blast-Simulating Irregular PTK in Rabbits","volume":"12","author":"Sampaio","year":"2023","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/tvst.13.8.22","article-title":"Effect of Topical Losartan in the Treatment of Established Corneal Fibrosis in Rabbits","volume":"13","author":"Martinez","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/ICO.0000000000003476","article-title":"Topical Losartan Inhibition of Myofibroblast Generation in Rabbit Corneas With Acute Incisions","volume":"43","author":"Martinez","year":"2024","journal-title":"Cornea"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.12.5.15","article-title":"Cell Biology of Spontaneous Persistent Epithelial Defects After Photorefractive Keratectomy in Rabbits","volume":"12","author":"Sampaio","year":"2023","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_23","first-page":"25158414251378124","article-title":"Topical losartan for established corneal fibrosis with machine learning-based predictors","volume":"17","author":"Lichtinger","year":"2025","journal-title":"Ther. Adv. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/ICO.0000000000003783","article-title":"Topical Losartan for Corneal Fibrosis: A Case Series With Densitometry Analysis","volume":"45","author":"Moloney","year":"2026","journal-title":"Cornea"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/ICO.0000000000003527","article-title":"Topical Losartan for Treating Corneal Haze After Ultraviolet-A\/Riboflavin Collagen Cross-Linking","volume":"43","author":"Rodgers","year":"2024","journal-title":"Cornea"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Vindel Valle, L.M., L\u00f3pez Alfaro, M.A., and Vindel Burchard, J.C. (2025). Treatment with losartan for visual rehabilitation post infectious keratitis: Case report. Arch. Soc. Esp. Oftalmol., in press.","DOI":"10.1016\/j.oftale.2025.502441"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3928\/1081597X-20221018-02","article-title":"Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience","volume":"38","author":"Bandeira","year":"2022","journal-title":"J. Refract. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000545215","article-title":"Topical Losartan Treatment of Herpes Simplex Virus- or Varicella-Zoster Virus-Induced Corneal Scarring: A Case Series","volume":"16","author":"Dutra","year":"2025","journal-title":"Case Rep. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1354\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T10:11:18Z","timestamp":1770631878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041354"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041354","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}